---
title: Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
date: '2023-10-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37870955/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231024180945&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: This 3-year analysis supported a continued long-term benefit
  of tebentafusp for overall survival among adult HLA-A*02:01-positive patients with
  previously untreated metastatic uveal melanoma. (Funded by Immunocore; IMCgp100-202
  ClinicalTrials.gov number, NCT03070392; EudraCT number, ...'
disable_comments: true
---
CONCLUSIONS: This 3-year analysis supported a continued long-term benefit of tebentafusp for overall survival among adult HLA-A*02:01-positive patients with previously untreated metastatic uveal melanoma. (Funded by Immunocore; IMCgp100-202 ClinicalTrials.gov number, NCT03070392; EudraCT number, ...